Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour‐related pain

BACKGROUND: A recent randomized‐withdrawal, active‐ and placebo‐controlled, double‐blind phase 3 study showed that tapentadol prolonged release (PR) was effective and well tolerated for managing moderate to severe, chronic malignant tumour‐related pain in patients who were opioid naive or dissatisfi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kress, H.G., Koch, E.D., Kosturski, H., Steup, A., Karcher, K., Dogan, C., Etropolski, M., Eerdekens, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071659/
https://www.ncbi.nlm.nih.gov/pubmed/27062079
http://dx.doi.org/10.1002/ejp.875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071659/
https://www.ncbi.nlm.nih.gov/pubmed/27062079
http://dx.doi.org/10.1002/ejp.875

Ejemplares similares